Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Sarcoma 1Other hematologic neoplasm 1NET 1Lymphoid 1Head & Neck 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Lymphoma, T-Cell, Peripheral 19Lymphoma, T-Cell, Cutaneous 18Lymphoma, T-Cell 17Lymphoma 16Lymphoma, Large B-Cell, Diffuse 9Leukemia, Lymphocytic, Chronic, B-Cell 9Mycosis Fungoides 8Lymphoma, Large-Cell, Anaplastic 8Multiple Myeloma 7Lymphoma, Non-Hodgkin 7Hodgkin Disease 7Lymphoma, Mantle-Cell 6Lymphoma, Follicular 6Lymphoma, B-Cell, Marginal Zone 5Immunoblastic Lymphadenopathy 5Burkitt Lymphoma 5Breast Neoplasms 5Waldenstrom Macroglobulinemia 4Sezary Syndrome 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Leukemia 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Lymphoma, Extranodal NK-T-Cell 3Lung Neoplasms 3Hematologic Neoplasms 3

Interventions

Docetaxel 277Prednisone 236enzalutamide 175Leuprolide 172Radiotherapy 164Abiraterone Acetate 153Magnetic Resonance Spectroscopy 147bicalutamide 137Goserelin 134Androgen Antagonists 111Radiosurgery 101acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 100apalutamide 78abiraterone 75gallium 68 PSMA-11 74Specimen Handling 67Gonadotropin-Releasing Hormone 58darolutamide 56Radiation 56Triptorelin Pamoate 53cabazitaxel 49Zoledronic Acid 49pembrolizumab 48Radiotherapy, Intensity-Modulated 47Flutamide 47Brachytherapy 47luprolide acetate gel depot 46Standard of Care 45Carboplatin 44Estramustine 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Prostatic Neoplasms × romidepsin × Clear all
NCT01638533 2025-02-07

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
37 enrolled
BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckLymphoidNETOther hematologic neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Glioma, Lung Neoplasms, Lymphoma, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Neuroendocrine Tumors, Hematologic Neoplasms

NCT00106301 2019-11-18

Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228

Celgene

Phase 2 Completed
2 enrolled
Genitourinary

Carcinoma, Renal Cell, Prostatic Neoplasms

NCT00106418 2019-11-18

A Research Study for Patients With Prostate Cancer

Celgene

Phase 2 Completed
35 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡